Should I Buy ANEB? ANEB 2026 Analysis

Should You Buy Anebulo Pharmaceuticals Inc (ANEB) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

0.880

1 Day change

2.34%

52 Week Range

3.420

Analysis Updated At

2026/01/29

Anebulo Pharmaceuticals Inc (ANEB) is not a strong buy for a beginner, long-term investor at this time. The stock shows no significant positive trading signals, weak financial performance, and lacks clear catalysts for growth. While the RSI indicates the stock is oversold, other technical indicators and the lack of institutional or insider activity suggest caution.

Technical Analysis

The MACD is positive but contracting, indicating weakening momentum. RSI is at 19.565, suggesting the stock is oversold. However, moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading below key resistance levels. The next support level is at 0.857, with resistance at 1.109.

Options Data

Positive Catalysts

The company is focusing on the intravenous formulation of selonabant for pediatric acute cannabis-induced toxicity, which could expedite approval and create future growth opportunities.

Neutral/Negative Catalysts

The company recently completed a tender offer, reducing the number of shareholders but at a significant premium to the current stock price. Financial performance is weak, with negative net income, declining EPS, and no revenue growth. There is no significant hedge fund or insider activity, and no recent congress trading data.

Financial Performance

In Q1 2026, the company reported no revenue growth (0% YoY), a net income loss of -$2,158,354 (-1.93% YoY), and a significant EPS decline of -37.50%. Gross margin remains at 0%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes are available for ANEB.

Analyst Rating

Wall Street analysts forecast ANEB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANEB is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 0.855

Low

Averages

High

Current: 0.855

Low

Averages

High

Maxim

Michael Okunewitch

Buy

Hold

downgrade

AI Analysis

2025-07-23

Reason

Maxim

Michael Okunewitch

Price Target

AI Analysis

2025-07-23

downgrade

Buy

Hold

Reason

Maxim analyst Michael Okunewitch downgraded Anebulo Pharmaceuticals to Hold from Buy.

Maxim

Buy

downgrade

$6 -> $3

2025-05-15

Reason

Maxim

Price Target

$6 -> $3

2025-05-15

downgrade

Buy

Reason

Maxim lowered the firm's price target on Anebulo Pharmaceuticals to $3 from $6 and keeps a Buy rating on the shares after its Q3 results. The company is prioritizing the advancement of IV selonbant into a Phase 1 SAD study in healthy adults, and the firm adjusting its price target to reflect this pivot, though Maxim remains positive on Anebulo given the unmet need in severe cannabis toxicity, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ANEB

Unlock Now

ANEB Should I Buy

ANEB Should I Buy

Should You Buy Anebulo Pharmaceuticals Inc (ANEB) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch